A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Trial ID or NCT#

NCT03861234

Status

recruiting iconRECRUITING

Purpose

This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.

Official Title

Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).

Eligibility Criteria

Ages Eligible for Study: Older than 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Quan Dong Nguyen, MD, MSc
Quan Dong Nguyen, MD, MSc
Ophthalmologist, Retina specialist, Uveitis and ocular inflammation specialist
Professor of Ophthalmology and, by courtesy, of Pediatrics and of Medicine (Immunology & Rheumatology)

Contact us to find out if this trial is right for you.

Contact

Quan Nguyen
+001 (650) 724-4280

SEND MESSAGE

View on ClinicalTrials.gov